Compare Inovio Pharmaceuticals Inc (INO) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Manchester United PLC — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Manchester United PLC trades at $22.66 (market cap $3.80B). The key difference: Manchester United PLC is far larger — about 48.4× Inovio Pharmaceuticals Inc's market cap, and Manchester United PLC pays a 1.26% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MANU | |
|---|---|---|
Market Cap | $78.55M | $3.80B |
Sector | Health | Media |
52-Week High | $2.87 | $23.53 |
52-Week Low | $0.66 | $15.10 |
Enterprise Value | $49.56M | $4.74B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Manchester United (MANU) trades at $22.60, up 4.15% today, with a bearish technical signal. The company reported Q1 2026 EPS of $0.04, beating expectations, but missed in Q4 2025. Revenue trends show modest growth to $667M in 2025, though net income remains negative. Key developments include securing land for a new stadium and Champions League qualification boosting future revenue prospects.
The outlook is mixed; stadium development and cost reductions offer long-term upside, but persistent losses and high debt pose risks. Analysts are cautious with 40% buy ratings. Investment opportunity hinges on operational turnaround, while risks include weak cash flow and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
